Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 12Prostatic Neoplasms 4Kidney Neoplasms 4Neoplasms 3Carcinoma, Hepatocellular 3Sarcoma, Ewing 2Osteosarcoma 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Medullary 2Carcinoma 2Adrenocortical Carcinoma 2von Hippel-Lindau Disease 1Wilms Tumor 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Sarcoma, Clear Cell 1

Interventions

lutetium Lu 177 dotatate 5Specimen Handling 3Magnetic Resonance Spectroscopy 3pembrolizumab 2olaparib 2fludarabine 2cabozantinib 2X-Rays 2Phantoms, Imaging 2Cyclophosphamide 2tivozanib 1repotrectinib 1pazopanib 1fludarabine phosphate 1entrectinib 1belinostat 1atezolizumab 1aldesleukin 1Yttrium-90 1Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Temozolomide 1Single Photon Emission Computed Tomography Computed Tomography 1Salts 1Positron Emission Tomography Computed Tomography 1PT-100 dipeptide 1Octreotide 1Nivolumab 1Introns 1Interferon alpha-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × cabozantinib × 30 days × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡